نتائج البحث - "Albert Deisseroth"

1

Supplementary Table S1. Use of Grouped Termsa for Summary Tabulations of Adverse Reactions from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb3c71a1ae3311a34043cbf269cfa88
https://doi.org/10.1158/1078-0432.22474197.v1

View record in OpenAIRE

2

Supplementary Figure S1 from FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

المؤلفون: Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be902c39ee395a68d595086357bb634
https://doi.org/10.1158/1078-0432.22469381.v1

View record in OpenAIRE

3

Data from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4633f148f2828c48b9597e5e86f99f2c
https://doi.org/10.1158/1078-0432.c.6528714

View record in OpenAIRE

4

Supplementary Figure S1. Study 20120148 - Hematological relapse-free survival for patients in CR1 by MRD level at baseline after at least 3 intensive chemotherapy blocks from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39411af126f6f2d40456d9d1f9609510
https://doi.org/10.1158/1078-0432.22474200

View record in OpenAIRE

5

Supplementary Table S1 from FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

المؤلفون: Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477f921b3577155839505aca83b12450
https://doi.org/10.1158/1078-0432.22469378

View record in OpenAIRE

6

Supplementary Tables S1 and S2 from FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

المؤلفون: Richard Pazdur, Gideon M. Blumenthal, Kirsten B. Goldberg, Albert Deisseroth, Frances Namuswe, Donna Przepiorka, Xu Michael Di, Michael L. Manning, Xianhua Cao, Chao Liu, Runyan Jin, Ruo-Jing Li

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3003c5aa3d26fdb8027857cee2a73583
https://doi.org/10.1158/1078-0432.22472799.v1

View record in OpenAIRE

7

Data from FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

المؤلفون: Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f76bad34dda06affe9b958f7b8772b
https://doi.org/10.1158/1078-0432.c.6527243

View record in OpenAIRE

8

Supplementary Table S3. Safety Population - Grade {greater than or equal to} 3 Adverse Reactions from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6276fd3c35307dfac0d1990907313a
https://doi.org/10.1158/1078-0432.22474191

View record in OpenAIRE

9

Supplementary Table S4. Literature Review - Efficacy Outcomes by MRD Log-Group for B-cell ALL CR1 using End-Of-Induction MRD Measurements from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4533a738fd2cd2640d0732376bb01c67
https://doi.org/10.1158/1078-0432.22474188.v1

View record in OpenAIRE

10

Supplementary Figure 1 from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

المؤلفون: Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fb0954902c2407558ec6d5284e8399
https://doi.org/10.1158/1078-0432.22476204.v1

View record in OpenAIRE

11

Supplementary Figure 2 from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

المؤلفون: Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d8d24c05387f09c3b40e96cbe4a207
https://doi.org/10.1158/1078-0432.22476201

View record in OpenAIRE

12

Data from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

المؤلفون: Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1510575c2978fec1ff3aeffe590f66ab
https://doi.org/10.1158/1078-0432.c.6529326

View record in OpenAIRE

13

Supplementary Table S5. Literature Review - Efficacy Outcomes by Binary MRD Level for B-cell ALL from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Richard Pazdur, Ann T. Farrell, Reena Philip, Albert Deisseroth, Rajeshwari Sridhara, Donna Roscoe, Yuan Li Shen, Donna Przepiorka, Aaron Schetter, Qing Xu, Emily Y. Jen

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8adeafe7dd1d5261c5de685bebe0fd02
https://doi.org/10.1158/1078-0432.22474185.v1

View record in OpenAIRE

14

Supplementary Tables from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

المؤلفون: Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e47caf63fa5983b418d915cdac7a6bb
https://doi.org/10.1158/1078-0432.22476195

View record in OpenAIRE

15

Data from FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

المؤلفون: Richard Pazdur, Gideon M. Blumenthal, Kirsten B. Goldberg, Albert Deisseroth, Frances Namuswe, Donna Przepiorka, Xu Michael Di, Michael L. Manning, Xianhua Cao, Chao Liu, Runyan Jin, Ruo-Jing Li

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ff4219aeff54fb4919590de0b901bd2
https://doi.org/10.1158/1078-0432.c.6528327

View record in OpenAIRE

16

Supplementary Figure 3 from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

المؤلفون: Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd67665c264cd0973ef818d22f014ad
https://doi.org/10.1158/1078-0432.22476198

View record in OpenAIRE

17

Supplementary Table S1 from FDA Approval: Blinatumomab

المؤلفون: Richard Pazdur, Ann T. Farrell, Qing Zhou, Ping Zhao, Pengfei Song, Deborah Schmiel, Tiffany K. Ricks, Nitin Mehrotra, Susan Kirshner, Robert C. Kane, Candace Gomez-Broughton, Brenda J. Gehrke, Haw-Jyh Chiu, Reyes Candau-Chacon, Carolyn L. Yancey, Albert Deisseroth, Chia-Wen Ko, Donna Przepiorka

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04eb5dd9d2864438c9fd3c493117694a
https://doi.org/10.1158/1078-0432.22457625.v1

View record in OpenAIRE

18

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

المؤلفون: Dickran Kazandjian, Albert Deisseroth, Flora Mulkey, Ann T. Farrell, R. Angelo de Claro, Ashley F. Ward, Emma C. Scott, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Richard Pazdur, Julia A. Beaver, Rajeshwari Sridhara, Kelly J. Norsworthy

المصدر: Clinical Cancer Research. 26:4280-4288

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4c46362fad430a5c472efca8f1b8e3
https://doi.org/10.1158/1078-0432.ccr-20-0834

View record in OpenAIRE

19

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

المؤلفون: Rosane Charlab, Vicky Hsu, Kelly J. Norsworthy, Ramadevi Gudi, Ann T. Farrell, Gene M. Williams, Kirsten B. Goldberg, Lola Luo, Albert Deisseroth, Sarah E. Dorff, Donna Przepiorka, Richard Pazdur, Yuan Li Shen, Christopher M. Sheth

المصدر: Clinical Cancer Research. 25:3205-3209

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e17204f9c190b9054ed4965817d072d
https://doi.org/10.1158/1078-0432.ccr-18-3749

View record in OpenAIRE

20

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

المؤلفون: Rajeshwari Sridhara, Qing Xu, Reena Philip, Yuan Li Shen, Aaron J. Schetter, Albert Deisseroth, Donna Przepiorka, Richard Pazdur, Donna Roscoe, Emily Y. Jen, Ann T. Farrell

المصدر: Clinical Cancer Research. 25:473-477

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Neoplasm, Residual, Adolescent, Gastroenterology, law.invention, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Randomized controlled trial, Refractory, law, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Internal medicine, Antibodies, Bispecific, medicine, Humans, Drug Approval, B cell, Aged, Aged, 80 and over, business.industry, Remission Induction, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Minimal residual disease, Confidence interval, Transplantation, Cytokine release syndrome, Treatment Outcome, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Female, Blinatumomab, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7606fcd3599fd2b7759fefbd480ff2f7
https://doi.org/10.1158/1078-0432.ccr-18-2337

View record in OpenAIRE

تنقيح النتائج